Zymeworks (ZYME) Competitors $15.23 +0.04 (+0.26%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, MLTX, and MTSRShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Krystal Biotech (NASDAQ:KRYS) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends. Which has preferable earnings and valuation, KRYS or ZYME? Krystal Biotech has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$290.52M14.07$89.16M$4.9228.70Zymeworks$76.30M15.00-$122.69M-$0.97-15.70 Is KRYS or ZYME more profitable? Krystal Biotech has a net margin of 40.85% compared to Zymeworks' net margin of -59.96%. Krystal Biotech's return on equity of 15.21% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech40.85% 15.21% 13.81% Zymeworks -59.96%-21.59%-16.52% Which has more volatility & risk, KRYS or ZYME? Krystal Biotech has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Does the media favor KRYS or ZYME? In the previous week, Krystal Biotech had 7 more articles in the media than Zymeworks. MarketBeat recorded 8 mentions for Krystal Biotech and 1 mentions for Zymeworks. Krystal Biotech's average media sentiment score of 1.24 beat Zymeworks' score of -0.07 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KRYS or ZYME? Krystal Biotech presently has a consensus target price of $210.38, indicating a potential upside of 48.98%. Given Krystal Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Krystal Biotech is more favorable than Zymeworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Zymeworks 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in KRYS or ZYME? 86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 13.7% of Krystal Biotech shares are owned by insiders. Comparatively, 1.9% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryKrystal Biotech beats Zymeworks on 13 of the 16 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworks IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$1.14B$2.38B$2.53B$10.03BDividend YieldN/A13.84%2.52%4.54%P/E Ratio-15.7025.7026.4026.29Price / Sales15.0014,734.70102.4681.86Price / CashN/A19.9723.1829.20Price / Book3.103.5332.176.43Net Income-$122.69M-$411.68M$16.40M$270.56M7 Day Performance8.71%1.08%1.62%3.01%1 Month Performance26.71%2.04%3.74%9.74%1 Year PerformanceN/A12.16%18.08%26.68% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks0.11 of 5 stars$15.23+0.3%N/AN/A$1.14B$76.30M-15.70460KRYSKrystal Biotech4.8894 of 5 stars$150.27+0.3%$210.38+40.0%-21.2%$4.35B$290.52M30.54210Positive NewsPCVXVaxcyte2.7096 of 5 stars$33.02+2.7%$130.00+293.7%-71.0%$4.29BN/A-8.03160Positive NewsACADACADIA Pharmaceuticals4.214 of 5 stars$25.26-0.9%$28.88+14.3%+58.0%$4.26B$957.80M18.99510News CoveragePositive NewsAnalyst ForecastACLXArcellx2.6381 of 5 stars$72.62+0.6%$114.31+57.4%-0.2%$4.03B$56.98M-21.2380Positive NewsADMAADMA Biologics3.6443 of 5 stars$16.87-0.2%$27.67+64.0%+1.0%$4.03B$426.45M19.62530Positive NewsARWRArrowhead Pharmaceuticals3.9999 of 5 stars$29.08+3.9%$43.14+48.4%+22.3%$4.02B$3.55M-22.72400MENSJyong BiotechN/A$52.31-5.1%N/AN/A$3.98BN/A0.0031MIRMMirum Pharmaceuticals3.2314 of 5 stars$76.06+2.5%$74.13-2.5%+88.2%$3.82B$336.89M-62.86140Positive NewsMLTXMoonLake Immunotherapeutics2.7625 of 5 stars$59.44-0.5%$74.43+25.2%+32.8%$3.82BN/A-21.382News CoveragePositive NewsHigh Trading VolumeMTSRMetseraN/A$35.87-1.2%$59.00+64.5%N/A$3.77BN/A0.0081News CoveragePositive NewsAnalyst Downgrade Related Companies and Tools Related Companies Krystal Biotech Alternatives Vaxcyte Alternatives ACADIA Pharmaceuticals Alternatives Arcellx Alternatives ADMA Biologics Alternatives Arrowhead Pharmaceuticals Alternatives Jyong Biotech Alternatives Mirum Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Metsera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYME) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
